CSIMarket
 
Biomarin Pharmaceutical Inc  (BMRN)
Other Ticker:  
 
 
Price: $83.8700 $-0.52 -0.616%
Day's High: $84.75 Week Perf: -2.48 %
Day's Low: $ 83.44 30 Day Perf: -2.49 %
Volume (M): 1,186 52 Wk High: $ 100.38
Volume (M$): $ 99,453 52 Wk Avg: $90.50
Open: $84.56 52 Wk Low: $76.02



 Market Capitalization (Millions $) 16,161
 Shares Outstanding (Millions) 193
 Employees 3,456
 Revenues (TTM) (Millions $) 2,419
 Net Income (TTM) (Millions $) 168
 Cash Flow (TTM) (Millions $) 31
 Capital Exp. (TTM) (Millions $) 108

Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes innovative therapies for people with rare genetic diseases. The company was founded in 1997 in California, and has since grown to become a global leader in the development of targeted therapies. BioMarin's mission is to deliver new treatments that can help people with rare diseases live longer, healthier lives.

BioMarin focuses on developing treatments for rare genetic diseases that are caused by the absence or malfunction of a single protein. These diseases often manifest in childhood and can have a devastating impact on patients and their families. In many cases, there are no approved treatments available, leaving patients with few options.

BioMarin's research and development efforts are focused on four core therapeutic areas: metabolic disorders, hemophilia, lysosomal storage disorders, and oncology. In metabolic disorders, the company is developing treatments for phenylketonuria (PKU) and achondroplasia, a form of dwarfism. In hemophilia, BioMarin is developing gene therapies that aim to cure patients of the disease. In lysosomal storage disorders, the company has developed treatments for Fabry disease and Pompe disease, and is working on treatments for mucopolysaccharidosis types I, II, and III. In oncology, BioMarin is developing a cancer immunotherapy that targets solid tumors.

BioMarin's flagship product is Palynziq, a treatment for PKU that was approved by the FDA in 2018. The company also markets Kuvan, Naglazyme, Vimizim, and Brineura, which are treatments for various rare diseases. BioMarin is committed to developing treatments that are safe and effective, and that can improve the lives of patients with rare genetic diseases.

BioMarin is headquartered in San Rafael, California, and has operations in the United States, Europe, Latin America, and Asia. The company has an experienced management team, and a strong financial position that allows it to invest in research and development. BioMarin is committed to working closely with patients, families, and advocacy groups to ensure that its treatments meet the needs of the rare disease community.


   Company Address: 770 Lindaro Street San Rafael 94901 CA
   Company Phone Number: 506-6700   Stock Exchange / Ticker: NASDAQ BMRN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CDXS   -7.76%    
• View Complete Report
   



Biomarin Pharmaceutical Inc

2 Subtitle options:Shareholders Disappointed as Biomarin Pharmaceutical Inc Reports Stagnant Earnings Despite Revenue Surge2.

Surge in Revenue Fails to Boost Earnings for Biomarin Pharmaceutical Inc in Q4 2023
Investors were taken by surprise as major pharmaceutical preparations company, Biomarin Pharmaceutical Inc (BMRN), reported stagnant earnings despite a substantial increase in revenue during the fourth quarter of the 2023 earnings season. Net profit per share remained unchanged at $0.11, marking a disappointment for shareholders.
BMRN's revenue, however, experienced a significant jump of 20.216% to $646.21 million compared to the same quarter in the previous year. This growth is noteworthy, especially considering the overall major pharmaceutical preparations sector experienced a decline of -15.67% in top-line revenue. Reflecting on the industry's performance, BMRN stands out with its revenue growth.

Biomarin Pharmaceutical Inc

Biomarin Pharmaceutical Inc Shines with Impressive Financial Turnaround in Q3 2023



Biomarin Pharmaceutical Inc, a major player in the Major Pharmaceutical Preparations industry, has released its financial results for the third quarter of 2023. The company's profits turned positive, showcasing a significant improvement compared to the previous year. Furthermore, despite a slight decrease in revenue compared to the previous quarter, the company still experienced considerable growth when compared to industry peers. This article will delve into the key findings of Biomarin Pharmaceutical's financial results, analyzing their potential impact on the company's future growth and prospects.
Financial Performance:
Biomarin Pharmaceutical Inc reported a positive earnings per share (EPS) of $0.21 in the third quarter of 2023, compared to a loss of $-0.04 per share in the same period a year ago. However, the income for the quarter saw a decline of 27.59% from the preceding reporting period. Despite this setback, the company's revenue experienced a remarkable growth of 15.036% year-on-year, reaching $581.33 million in Q3 2023.

Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc's EPS Soars by 93.33%, Records 11.517% Revenue Boost in Q2, Dwarfing Major Pharmaceutical Sector Growth

Biomarin Pharmaceutical Inc: A Bullish Outlook Amidst Impressive Financial Results
In a resounding show of strength and resilience, Biomarin Pharmaceutical Inc has delivered exceptional financial results for the fiscal interval ending June 30, 2023. The Major Pharmaceutical Preparations company has not only outperformed its sector contemporaries on the top-line side but has also seen substantial improvements across various key metrics.
One of the most noteworthy achievements for Biomarin Pharmaceutical Inc is the remarkable increase in income per share by 93.33% to $0.29 per share compared to the prior year period. This significant growth signifies the company's ability to generate substantial earnings and instills confidence in its future prospects.

Biomarin Pharmaceutical Inc

Earnings deteriorated Regardless of Strong revenue by in the financial span closing March 31 2023

Biomarin Pharmaceutical Inc (BMRN) has recently released its financial report for the first quarter of 2023.
Despite an increase in net income growth from the previous quarter, the company's return on assets (ROA) fell to 1.09%, although this still surpassed the company's average ROA of -2.32%.
The healthcare sector boasted 30 other companies with a higher ROA than BMRN, but the company managed to improve its overall ROA ranking - growing from 2020 in the fourth quarter of 2022 to 406 in the first quarter of 2023.






 

Biomarin Pharmaceutical Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Biomarin Pharmaceutical Inc does not provide revenue guidance.

Earnings Outlook
Biomarin Pharmaceutical Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com